nivolumab

Documents about nivolumab

• Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig#1340586ClinicalTrials.gov
• Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer#1337251ClinicalTrials.gov
• Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients#300249ClinicalTrials.gov
• Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma#424198ClinicalTrials.gov
• Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma#1114118ClinicalTrials.gov
• CARG, VES13, G8 Scales in Predicting Drug Toxicity in Patients Receiving Nivolumab#1486163ClinicalTrials.gov
• Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma#1231984ClinicalTrials.gov
• Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide#1445716ClinicalTrials.gov
• Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)#1487104ClinicalTrials.gov
• A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma#1397648ClinicalTrials.gov
• Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy#1307034ClinicalTrials.gov
• Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma#181757ClinicalTrials.gov
• ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma#835920ClinicalTrials.gov
• A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma#895380ClinicalTrials.gov
• Regorafenib and Nivolumab Simultaneous Combination Therapy#919090ClinicalTrials.gov
• Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)#992355ClinicalTrials.gov
• A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma#847532ClinicalTrials.gov
• Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma#1060896ClinicalTrials.gov
• A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma#1228586ClinicalTrials.gov
• Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin#1443159ClinicalTrials.gov
• Phase II study of axitinib intensification compared to nivolumab alone after induction with ipilimumab plus nivolumab in patients with mRCC without previous complete response (AxIn study)#1500858IRIS
• An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma#623525ClinicalTrials.gov
• Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma#841725ClinicalTrials.gov
• Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer#847303ClinicalTrials.gov
• Recurrent/Metastatic Olfactory Neuroblastoma: Evaluating the Efficacy and Safety of Nivolumab#851859ClinicalTrials.gov
• First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)#886490ClinicalTrials.gov
• SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer#1260938ClinicalTrials.gov
• Large Granular Lymphocytes in mNSCLC Treated With Nivolumab#1446095ClinicalTrials.gov
• Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery#373603ClinicalTrials.gov
• A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma#801205ClinicalTrials.gov
• An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia#831912ClinicalTrials.gov
• A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers#851682ClinicalTrials.gov
• A Study to Evaluate Nivolumab in Japanese Participants With Muscle-invasive Urothelial Carcinoma#887337ClinicalTrials.gov
• A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer#979697ClinicalTrials.gov
• Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer#1114620ClinicalTrials.gov
• Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC#1443187ClinicalTrials.gov
• Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma#1485738ClinicalTrials.gov
• A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma#329535ClinicalTrials.gov
• Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer#843074ClinicalTrials.gov
• CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma#1044405ClinicalTrials.gov
• Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED#1058901ClinicalTrials.gov
• Fedratinib in Combination With Nivolumab#1114868ClinicalTrials.gov
• Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC#1409548ClinicalTrials.gov
• Post-ATU Study of Nivolumab#28315ClinicalTrials.gov
• Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma#967007ClinicalTrials.gov
• PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma#1161486ClinicalTrials.gov
• Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC#1230846ClinicalTrials.gov
• A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)#1243206ClinicalTrials.gov
• Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC#1309540ClinicalTrials.gov
• ASCT With Nivolumab in Patients With Multiple Myeloma#1365750ClinicalTrials.gov